NASDAQ$SDGR

Schrodinger Inc/United States · Q4 2020 earnings

Q4 2020 earnings · · Investor relations

Briefing

Schrödinger reported revenue growth driven by software uptake and strategic collaborations.

Schrödinger reported a 28% increase in total revenue for Q4 2020, driven by strong software revenue growth and contributions from a strategic collaboration with Bristol Myers Squibb. The company ended the year with a solid financial position, enabling continued investment in its computational platform and internal pipeline.

  • Total revenue increased by 28% in the fourth quarter of 2020.
  • Software revenue increased by 42% in the fourth quarter of 2020.
  • Entered into a strategic collaboration with Bristol Myers Squibb, receiving $55 million upfront.
  • Ended the fourth quarter with $643.2 million in cash, cash equivalents, restricted cash and marketable securities.

Headline financials

Total Revenue

$33M

Previous: $25.8M+27.9%
EPS (adj)

-$0.18

Previous: -$1.11+83.8%
Software Gross Margin

77.0%

Previous: 79.0%-2.5%
Capital Expenditures

$886K

No prior period
Free Cash Flow

$42.7M

No prior period
Net Income

-$11.1M

Previous: -$6.77M-64.0%
Operating Income

-$35.6M

Previous: -$7.85M-353.7%
Gross Profit

$19M

Previous: $15.5M+22.4%
Cash & Equivalents

$202M

No prior period
Total Assets

$746M

No prior period
Stock-Based Comp

$3M

No prior period

Revenue & EPS history

Schrodinger · Revenue · Quarterly

$33M

Q4 2020+27.9%vs Q4 2019
Beat estimate in 7 of 11 quarters(64%)
ActualEstimate

Revenue by segment

Schrodinger · $33.1M total across 2 segments · Q4 2020

  • Software Products & Services
    $25M+42.0%
  • Drug Discovery
    $8.1M-2.4%

Forward guidance

Schrödinger expects total revenue to range from $124 million to $142 million, with software revenue expected to range from $102 million to $110 million, and drug discovery revenue expected to range from $22 million to $32 million for the fiscal year ended December 31, 2021.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2020

Historical avgQ4 2020

-2.2%

Avg return

Earnings day

-1.6%

Avg return

5 days after

+1.8%

Avg return

30 days after

42%

11 / 26 earnings

Positive

+31.4%

Q4 2021

Best reaction

-29.9%

Q4 2020

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.2%+1.9%+23.0%
Q4 2025+8.3%+5.9%-6.1%
Q3 2025-5.8%-7.4%-10.8%
Q1 2025+0.6%+0.2%+3.8%
Q4 2024+2.5%-2.9%-8.0%
Q3 2024+13.1%-5.1%+7.8%
Q2 2024+0.1%-15.7%-6.8%
Q1 2024-4.9%-1.4%-11.7%
Q4 2023-23.1%-23.7%-18.4%
Q3 2023+15.3%+27.5%+49.7%
Q2 2023-26.9%-27.3%-29.8%
Q1 2023-5.1%-6.4%+22.3%
Q4 2022+14.5%+21.7%+16.8%
Q3 2022-14.6%-15.6%-29.2%
Q2 2022+1.5%-4.9%-19.1%
Q1 2022-5.5%-10.5%+1.5%
Q4 2021+31.4%+45.4%+36.4%
Q3 2021-16.1%-15.6%-31.6%
Q2 2021-5.1%-12.1%-0.1%
Q1 2021-6.8%-4.3%+19.4%
Q4 2020-29.9%-29.7%-20.8%
Q3 2020+12.4%+15.8%+39.6%
Q3 2019+12.4%+15.8%+39.6%
Q2 2020-2.5%-2.4%-24.2%
Q1 2020-8.1%+0.5%+3.0%
Q4 2019-14.6%+8.3%+1.5%
Q2 2019
Q1 2019
Q4 2018
Q3 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro